TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24890738

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 5 μg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 2.5 μg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 1.25 μg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo Respimat®
Number of subjects: 149
Study: 23018285

Group type: EXPERIMENTAL
Intervention: Avagacestat 200 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Avagacestat 400 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Avagacestat 50 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 20732631

Group type: EXPERIMENTAL
Intervention: Teacher-delivered personality-targeted intervention
Number of subjects: 2506

Group type: COMPARATOR
Intervention: Nontreatment condition
Number of subjects: 2506
Study: 18183940

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study: 15373868

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bipolar diathermy
Number of subjects: 21
Study: 11240120

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity in deaf subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contrast sensitivity in hearing subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contrast sensitivity in hearing native signers
Number of subjects: 0
Study: 9322631

Group type: COMPARATOR
Intervention: Prepidil (intracervical prostaglandin E2 gel)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cervidil (controlled-release hydrogel pessary)
Number of subjects: 73
Study: 8173721

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 gram single dose)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2 grams)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 461

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Ceftizoxime and Cefoxitin
Number of subjects: 461
Study: 2895596

Group type: EXPERIMENTAL
Intervention: Single small oral dose of a beta-adrenergic blocking agent (labetalol, atenolol, or oxprenolol)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 128
Study: 29068040

Group type: EXPERIMENTAL
Intervention: 1 MAC desflurane
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5 MAC desflurane
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.0 MAC desflurane
Number of subjects: 36
Study: 28969655

Group type: EXPERIMENTAL
Intervention: Educational interventions including lecture and group discussion along with standard well baby care
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard well baby care
Number of subjects: 104
Study: 25644349

Group type: EXPERIMENTAL
Intervention: 400 IU/d of vitamin D3 supplementation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3 supplementation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no supplementation)
Number of subjects: 51
Study: 22562960

Group type: EXPERIMENTAL
Intervention: 10 g testosterone gel daily for 6 months
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 19395280

Group type: EXPERIMENTAL
Intervention: Insulin pump infusion line not changed for up to 100 hours
Number of subjects: 20
Study: 18307075

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 93
Study: 17140521

Group type: EXPERIMENTAL
Intervention: ART method
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 217

Group type: COMPARATOR
Intervention: Rotating instruments (Control)
Number of subjects: 217
Study: 12768426

Group type: EXPERIMENTAL
Intervention: Shot put performance
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: One-arm seated shot put
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Elbow extensors' isokinetic torque
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bench-press tests
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Estimated arm muscle cross-sectional area
Number of subjects: 13
Study: 11099990

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic conversion strategy (n = 27)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rate-control strategy (n = 23)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic strategy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic arm
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rate-control arm
Number of subjects: 50
Study: 8958014

Group type: EXPERIMENTAL
Intervention: Vaginal endosonography
Number of subjects: 17

Group type: COMPARATOR
Intervention: Proctography
Number of subjects: 17
Study: 1396252

Group type: EXPERIMENTAL
Intervention: Surfactant-TA (100 mg/kg) administered within 30 min of birth (early group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Surfactant-TA (100 mg/kg) administered at 6 h of age (late group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Surfactant-TA (100 mg/kg) administered early
Number of subjects: 32
Study: 4039775

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCL, Paspertin, loading infusion 0.5 mg/kg body wt./h over 2 h, maintenance infusion 0.25 mg/kg/h over 24 h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Haloperidol (HAL, Haldol, 1/10 of MCL dosage)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Triflupromazine (TFP, Psyquil, 1/2 of MCL dosage)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Haloperidol (HAL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Triflupromazine (TFP)
Number of subjects: 22
Study: 31557306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 604
Study: 30422789

Group type: EXPERIMENTAL
Intervention: Pro-drinking user-generated comments (UGCs) with high user engagement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anti-drinking user-generated comments (UGCs) with high user engagement
Number of subjects: 120
Study: 27219465

Group type: EXPERIMENTAL
Intervention: Structured exercise training programme (SETP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (3 mg drospirenone plus 30 μg ethinyloestradiol)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Polyvitamin tablets
Number of subjects: 150
Study: 22385102

Group type: EXPERIMENTAL
Intervention: Combination peel with fractional prickle coral calcium (FCR™)
Number of subjects: 16
Study: 22809091

Group type: EXPERIMENTAL
Intervention: Fixed combination brimonidine-timolol (FCBT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (artificial tear)
Number of subjects: 105
Study: 20138102

Group type: COMPARATOR
Intervention: 5-HTP administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17885522

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 15628945

Group type: EXPERIMENTAL
Intervention: Gliclazide (interchange group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Glibenclamide (reference group)
Number of subjects: 116
Study: 11394491

Group type: EXPERIMENTAL
Intervention: TENS applied over the median nerve for 15 minutes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TENS applied to the Hegyu acupuncture point (L.I.4) for 15 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no TENS)
Number of subjects: 30
Study: 9591928

Group type: EXPERIMENTAL
Intervention: Amrinone (1-270 microg x min(-1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Enoximone (1-270 microg x min(-1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Theophylline (5-1500 microg x min(-1))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (2-877 microg x min(-1))
Number of subjects: 18
Study: 8209275

Group type: EXPERIMENTAL
Intervention: Cisplatin-containing chemotherapy plus radiotherapy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Mitomycin/ifosfamide/cisplatin (MIC) plus radiotherapy
Number of subjects: 500
Study: 3059277

Group type: EXPERIMENTAL
Intervention: Vancomycin (10 mg/kg I.V. q 6 H, day -5 to +1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no vancomycin)
Number of subjects: 60
Study: 30261905

Group type: EXPERIMENTAL
Intervention: Synbiotics (Bifidobacterium breve strain Yakult, Lactobacillus casei strain Shirota, and galactooligosaccharides)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No‐Synbiotics
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 72
Study: 28257160

Group type: COMPARATOR
Intervention: Protein 0 g (control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Protein 12.5 g
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Protein 25 g
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Protein 50 g
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Protein 75 g
Number of subjects: 27
Study: 26403339

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy at various doses (grouped as >0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50% of target dose)
Number of subjects: 6682

Group type: EXPERIMENTAL
Intervention: >0% to 12.5% of target dose
Number of subjects: 6682

Group type: EXPERIMENTAL
Intervention: >12.5% to 25% of target dose
Number of subjects: 6682

Group type: EXPERIMENTAL
Intervention: >25% to 50% of target dose
Number of subjects: 6682

Group type: COMPARATOR
Intervention: No beta-blocker therapy
Number of subjects: 6682
Study: 23454885

Group type: EXPERIMENTAL
Intervention: Exposure to smoking cues in movies (one-hour movie clip with smoking characters)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Exposure to movies without smoking characters (control group)
Number of subjects: 65
Study: 21290983

Group type: EXPERIMENTAL
Intervention: CinA+ (sugared chewing gum containing cinnamic aldehyde and natural flavors)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CinA- (sugared chewing gum without cinnamic aldehyde but with natural flavors)
Number of subjects: 15

Group type: COMPARATOR
Intervention: GB (non-sugared chewing gum base without any flavors and without cinnamic aldehyde)
Number of subjects: 15
Study: 19085498

Group type: EXPERIMENTAL
Intervention: 20 mL ropivacaine (0.2%) intraarticularly plus 30 mL saline in the extraarticular wound space
Number of subjects: 32

Group type: COMPARATOR
Intervention: 20 mL ropivacaine (0.2%) intraarticularly plus 30 mL ropivacaine (0.2%) in the extraarticular wound space
Number of subjects: 32
Study: 17205877

Group type: EXPERIMENTAL
Intervention: Single dose of 1% tropicamide and 10% phenylephrine (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Three doses of 1% tropicamide and 10% phenylephrine (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison of pupil size between Group A and Group B
Number of subjects: 80
Study: 14581307

Group type: EXPERIMENTAL
Intervention: Disease Management Program (DMP) with 6 home visits by a cardiac-trained nurse
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Disease Management Program (DMP)
Number of subjects: 146
Study: 16049609

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10609067

Group type: EXPERIMENTAL
Intervention: APF+ patients (positive for APF)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: RF+APF+ patients
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: RF+APF- and RF-APF+ patients
Number of subjects: 249

Group type: COMPARATOR
Intervention: RF+APF- patients
Number of subjects: 249

Group type: COMPARATOR
Intervention: RF-APF+ patients
Number of subjects: 249

Group type: COMPARATOR
Intervention: RF-APF- patients
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: APF+ patients
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: RF+ and RF- patients
Number of subjects: 249
Study: 7577294

Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia with Bupivacaine 0.5% (20 ml) at L2-3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia
Number of subjects: 10
Study: 1850789

Group type: EXPERIMENTAL
Intervention: Interactive videodisc program (n = 42)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Traditional lecture method (n = 41)
Number of subjects: 83
Study: 7261940

Group type: EXPERIMENTAL
Intervention: Propranolol in fixed combinations with triamteren and hydrochlorothiazide (Dociteren)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol with increased diuretic component
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Laboratory tests during treatment
Number of subjects: 19
Study: 28558941

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 24

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 24
Study: 25424991

Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 g four times daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Valganciclovir (900 mg daily)
Number of subjects: 119
Study: 23406721

Group type: EXPERIMENTAL
Intervention: Peer-led self-management support intervention
Number of subjects: 58
Study: 20959530

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day) with exercise training (1.5-2 h/day, 3 days/wk)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pioglitazone (30 mg/day) alone
Number of subjects: 44
Study: 19212305

Group type: EXPERIMENTAL
Intervention: Current treatment for hepatitis C
Number of subjects: 170000000

Group type: EXPERIMENTAL
Intervention: Specifically Targeted Antiviral Therapy for HCV (STAT-C)
Number of subjects: 170000000
Study: 17556788

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Pravastatin 10mg
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Number of subjects: 2268
Study: 15213207

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg daily
Number of subjects: 2808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2808

Group type: EXPERIMENTAL
Intervention: Pooled hormone therapy (CEE combined with CEE plus MPA)
Number of subjects: 2808
Study: 11711348

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9549834

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg sublingual tablet)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7528449

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) after successful cytoreductive chemotherapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during induction, consolidation, and the first two cycles of maintenance chemotherapy
Number of subjects: 67
Study: 3382060

Group type: EXPERIMENTAL
Intervention: Oral metaproterenol sulfate (MS) 0.4 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral metaproterenol sulfate (MS) 0.6 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral metaproterenol sulfate (MS) 0.8 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31416827

Group type: COMPARATOR
Intervention: Dexamethasone (0.6 mg/kg)
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (0.15 mg/kg)
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg)
Number of subjects: 1252
Study: 27886678

Group type: EXPERIMENTAL
Intervention: Standard patellar bone resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified patellar bone resection
Number of subjects: 0
Study: 25646337

Group type: COMPARATOR
Intervention: Iron‐folic acid (IFA) capsule
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN) capsule
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: 20-g sachet of small‐quantity lipid‐based nutrient supplement (SQ‐LNS)
Number of subjects: 1391
Study: 24029861

Group type: EXPERIMENTAL
Intervention: Narrow-band ultraviolet B (NB-UVB) exposures
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oral cholecalciferol 20 µg daily
Number of subjects: 14
Study: 22204658

Group type: EXPERIMENTAL
Intervention: 6-month scale and polish
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: 12-month scale and polish
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: 24-month scale and polish
Number of subjects: 307
Study: 20818838

Group type: EXPERIMENTAL
Intervention: Gabapentin ER QD (total daily dose 1800 mg)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Gabapentin ER DD (total daily dose 1800 mg)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study: 17995820

Group type: EXPERIMENTAL
Intervention: Chocolate mix with 2.45 g of milk proteins
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chocolate mix without milk proteins
Number of subjects: 24
Study: 15975326

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acarabose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triflusal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin treatment to lower homocysteine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormonal replacement in post‐menopausal women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic, anticoagulant and surgical treatments
Number of subjects: 0
Study: 12072678

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 0.015 mg/kg midazolam
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg midazolam
Number of subjects: 98
Study: 9854344

Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Reminder (any type)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Postal reminder
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Manual telephone reminder
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Automated telephone reminder
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: All reminder methods combined
Number of subjects: 500
Study: 7830025

Group type: EXPERIMENTAL
Intervention: Low-intensity intervention
Number of subjects: 76

Group type: COMPARATOR
Intervention: Medium-intensity intervention
Number of subjects: 76
Study: 2361810

Group type: COMPARATOR
Intervention: Exercise only (E)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Energy restriction only (D)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 121
Study: 467206

Group type: EXPERIMENTAL
Intervention: X-Prep Liquid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divided dose of X-Prep Liquid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Castor oil
Number of subjects: 0
Study: 30701704

Group type: EXPERIMENTAL
Intervention: Fluoride-free microcrystalline hydroxyapatite (HAP) dentifrice
Number of subjects: 150

Group type: COMPARATOR
Intervention: 1400 ppm fluoride control dentifrice
Number of subjects: 150
Study: 28723943

Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 25751215

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg)
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Placebo (folic acid)
Number of subjects: 1228
Study: 23599353

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (HBCR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: In-hospital rehabilitation
Number of subjects: 100
Study: 21561348

Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal polypropylene-mesh repair kit
Number of subjects: 389

Group type: COMPARATOR
Intervention: Traditional colporrhaphy
Number of subjects: 389
Study: 19453810

Group type: EXPERIMENTAL
Intervention: Two-compound scalp formulation (calcipotriol 50 microg/g plus betamethasone 0.5 mg/g as dipropionate; Xamiol)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Calcipotriol scalp solution (50 microg/mL; Daivonex)
Number of subjects: 312
Study: 16952680

Group type: EXPERIMENTAL
Intervention: Preoperative reading
Number of subjects: 17

Group type: COMPARATOR
Intervention: No preoperative reading
Number of subjects: 17
Study: 14872413

Group type: EXPERIMENTAL
Intervention: 300 microg/kg rFVIIa within 1 to 2 hours of bleed onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: 90 microg/kg rFVIIa every 2 to 3 hours for two or three doses
Number of subjects: 0
Study: 11380520

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 16
Study: 9250456

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 75
Study: 8488916

Group type: EXPERIMENTAL
Intervention: Pressure patching (group 1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Light patching (group 2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Unpatched fellow eye (group 3)
Number of subjects: 27
Study: 3631470

Group type: EXPERIMENTAL
Intervention: Nalbuphine 3 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pethidine 15 mg
Number of subjects: 60
Study: 31952047

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3) supplementation (0.3 g/kg body mass)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo supplements (amylum solani, magnesium stearate, and sunflower oil capsules)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3) supplementation
Number of subjects: 32
Study: 29683200

Group type: EXPERIMENTAL
Intervention: Long-axis, in-plane approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Short-axis, out-of-plane approach
Number of subjects: 40